SIGLEC1 (CD169): a marker of active neuroinflammation in the brain but not in the blood of multiple sclerosis patients
Abstract We aimed to evaluate SIGLEC1 (CD169) as a biomarker in multiple sclerosis (MS) and Neuromyelitis optica spectrum disorder (NMOSD) and to evaluate the presence of SIGLEC1+ myeloid cells in demyelinating diseases. We performed flow cytometry-based measurements of SIGLEC1 expression on monocyt...
Guardado en:
Autores principales: | Lennard Ostendorf, Philipp Dittert, Robert Biesen, Ankelien Duchow, Victoria Stiglbauer, Klemens Ruprecht, Judith Bellmann-Strobl, Dominik Seelow, Werner Stenzel, Raluca A. Niesner, Anja E. Hauser, Friedemann Paul, Helena Radbruch |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9dbd84d824d44f7f9ebb0bb35db75826 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Parallelized TCSPC for dynamic intravital fluorescence lifetime imaging: quantifying neuronal dysfunction in neuroinflammation.
por: Jan Leo Rinnenthal, et al.
Publicado: (2013) -
Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9
por: Ernesto Rodriguez, et al.
Publicado: (2021) -
Siglecs as Therapeutic Targets in Cancer
por: Jackwee Lim, et al.
Publicado: (2021) -
Acta Nº169
por: Banco Central de Chile
Publicado: (2019) -
Identification of Siglec-1 null individuals infected with HIV-1
por: Javier Martinez-Picado, et al.
Publicado: (2016)